Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing –Remitting Multiple Sclerosis in the United States
ConclusionTreatment with ozanimod was associated with substantial reductions in annual drug costs and total MS-related healthcare costs to avoid relapses compared with other DMTs. In the fixed-budget analysis, ozanimod demonstrated a favorable cost-effective profile relative to other DMTs.
Source: Neurology and Therapy - Category: Neurology Source Type: research
More News: Avonex | Betaseron | Brain | Clinical Trials | Copaxone | Gilenya | Healthcare Costs | Multiple Sclerosis | Neurology | Rebif | Study | USA Health